Payden & Rygel’s CVS Health CVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $22.6M | Buy |
218,700
+5,600
| +3% | +$500K | 1.74% | 15 |
|
|
2026
Q1 | $15.3M | Sell |
213,100
-47,100
| -18% | -$3.63M | 1.18% | 32 |
|
|
2025
Q4 | $20.6M | Sell |
260,200
-1,300
| -0.5% | -$102K | 1.43% | 21 |
|
|
2025
Q3 | $19.7M | Buy |
+261,500
| New | +$17.9M | 1.63% | 19 |
|
|
2024
Q4 | – | Sell |
-99,900
| Closed | -$6.28M | – | 128 |
|
|
2024
Q3 | $6.28M | Buy |
+99,900
| New | +$5.83M | 0.48% | 69 |
|
|
2024
Q2 | – | Sell |
-183,500
| Closed | -$14.6M | – | 127 |
|
|
2024
Q1 | $14.6M | Sell |
183,500
-135,500
| -42% | -$10.4M | 0.69% | 57 |
|
|
2023
Q4 | $25.2M | Buy |
319,000
+35,600
| +13% | +$2.53M | 1.75% | 10 |
|
|
2023
Q3 | $19.8M | Buy |
283,400
+182,000
| +179% | +$12.9M | 1.35% | 16 |
|
|
2023
Q2 | $7.01M | Buy |
101,400
+97,300
| +2,373% | +$6.92M | 0.5% | 80 |
|
|
2023
Q1 | $305K | Sell |
4,100
-432,100
| -99% | -$36.2M | 0.02% | 109 |
|
|
2022
Q4 | $40.6M | Buy |
436,200
+29,000
| +7% | +$2.8M | 2.17% | 8 |
|
|
2022
Q3 | $38.8M | Buy |
407,200
+8,700
| +2% | +$861K | 2.27% | 3 |
|
|
2022
Q2 | $36.9M | Buy |
398,500
+821
| +0.2% | +$80.1K | 2.22% | 8 |
|
|
2022
Q1 | $40.2M | Sell |
397,679
-114,700
| -22% | -$12M | 2.03% | 10 |
|
|
2021
Q4 | $52.9M | Sell |
512,379
-2,200
| -0.4% | -$203K | 2.44% | 1 |
|
|
2021
Q3 | $43.7M | Buy |
514,579
+235,300
| +84% | +$19.7M | 2.27% | 4 |
|
|
2021
Q2 | $23.3M | Sell |
279,279
-147,837
| -35% | -$12.1M | 1.11% | 47 |
|
|
2021
Q1 | $32.1M | Buy |
427,116
+16,716
| +4% | +$1.22M | 1.49% | 27 |
|
|
2020
Q4 | $28M | Buy |
410,400
+128,100
| +45% | +$8.33M | 1.44% | 35 |
|
|
2020
Q3 | $16.5M | Sell |
282,300
-76,600
| -21% | -$4.77M | 0.98% | 58 |
|
|
2020
Q2 | $23.3M | Sell |
358,900
-1,100
| -0.3% | -$69.3K | 1.49% | 32 |
|
|
2020
Q1 | $21.4M | Buy |
360,000
+15,271
| +4% | +$1.02M | 1.54% | 31 |
|
|
2019
Q4 | $25.6M | Sell |
344,729
-250,200
| -42% | -$17.6M | 1.6% | 33 |
|
|
2019
Q3 | $37.5M | Buy |
594,929
+108,129
| +22% | +$6.41M | 2.55% | 5 |
|
|
2019
Q2 | $26.5M | Buy |
486,800
+229,800
| +89% | +$12.4M | 1.82% | 20 |
|
|
2019
Q1 | $13.9M | Buy |
+257,000
| New | +$15.9M | 1.01% | 52 |
|
|
2016
Q1 | – | Sell |
-187
| Closed | -$18K | – | 173 |
|
|
2015
Q4 | $18K | Buy |
+187
| New | +$18.3K | ﹤0.01% | 144 |
|
Other funds holding CVS
Payden & Rygel's CVS Position: Q2 2026 in Review
Payden & Rygel increased its CVS Health (CVS) stake by 2.6% in Q2 2026, buying an estimated $500K and bringing the position to 218,700 shares worth $22.6M. The position accounts for 1.74% of the portfolio, ranked #15.
Payden & Rygel first reported a position in CVS in Q4 2015 and has held it in 27 quarters since. The position peaked at $52.9M in Q4 2021. 2,080 funds tracked by Wall St. Rank hold CVS as of Q2 2026.
- Payden & Rygel held 218,700 shares of CVS Health worth $22.6M as of Q2 2026.
- Payden & Rygel bought 5,600 CVS Health shares in Q2 2026, an estimated $500K.
- CVS Health made up 1.74% of Payden & Rygel's portfolio in Q2 2026, its #15 holding.
- Payden & Rygel first reported a position in CVS Health in Q4 2015 and has held it in 27 quarters since.
- Payden & Rygel's CVS Health position peaked at $52.9M in Q4 2021.
- 2,080 funds tracked by Wall St. Rank held CVS Health as of Q2 2026.
Based on Payden & Rygel's 13F filing for Q2 2026, filed 31 Jul 2026.